Newsfeeds Archive - Page 20 of 56

2 minute read

Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement

June 15, 8:17 PM

UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its latest non-brokered private placement as well as an upsizing of the original financing option to $4 million.

AWKNF

3 minute read

MAPS’ Psychedelic Science 2023: Gov. Polis To Open Event, New Shulgin Compounds To Be Revealed

By Lara Goldstein

June 14, 9:50 AM

Psychedelic Science, this year’s gathering hosted by the legendary nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its final agenda, which will include opening remarks by Colorado Governor Jared Polis, featured speakers and a new local day-pass option.

ATAI

2 minute read

Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M

By Lara Goldstein

June 13, 10:16 PM

MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of its units at a price of $0.22 (CA$0.30) each, corresponding to aggregate gross proceeds of minimum $752,300 (CA$1 million,) and maximum $3.76 (CA$5 million.)

PMBHF

2 minute read

Silo Pharma’s New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making

By Lara Goldstein

June 13, 2:05 PM

Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.

SILO

3 minute read

Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah’s Guest, Swiss MDMA & More

By Lara Goldstein

June 13, 10:31 AM

Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research

BETRF

1 minute read

Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific

By Lara Goldstein

June 12, 6:53 PM

Psychedelics drug developer Wesana Health Holdings Inc. (OTCQB: WSNAF) announced all matters discussed at the company’s annual general and special shareholders meeting of June 9 were approved by a majority of votes cast.

LSDI

2 minute read

Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia

By Lara Goldstein

June 12, 3:48 PM

The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S

PMBHF

2 minute read

Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism

By Lara Goldstein

June 12, 3:18 PM

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of its intellectual property (IP.)

AWKNF

2 minute read

BetterLife’s Non-Hallucinogenic LSD’s Clinical Studies, Braxia’s Psychedelic Treatments Continue

By Lara Goldstein

June 9, 4:45 PM

Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting Major Depressive Disorder (MDD.)

BETRF